# QIAGEN account plan

> QIAGEN sells Sample to Insight molecular testing kits, instruments and bioinformatics; FY2025 net sales of $2,090.0 million.

## At a glance

QIAGEN N.V. is a Dutch holding company headquartered in Venlo, listed on the NYSE (QGEN) and in Frankfurt (QIA). It sells sample preparation, assays, instruments and bioinformatics software to more than 500,000 customers in Life Sciences (academia, pharma, forensics) and molecular diagnostics, delivering to more than 160 countries. In FY2025 net sales were $2,090.0 million (+6%), operating income $465.9 million (22.3% margin) and net income $424.9 million; consumables and related revenues made 90% of sales. It employed about 5,500 people as of 30 June 2026. Jonathan M. Pratt became CEO on 1 September 2026, succeeding Thierry Bernard.

## Business units

- **Diagnostic solutions** (38% of FY2025 net sales ($803.1 million)): Regulated molecular testing platforms and consumables for clinical healthcare, including the QuantiFERON latent TB test and the QIAstat-Dx syndromic PCR system, plus companion diagnostics co-development with pharma. In 2025 QIAstat-Dx sales rose 27% and QuantiFERON-TB 11%. In Q2 2026 the group made $204 million (-2% CER) as U.S. immigration testing fell.
- **Sample technologies** (32% of FY2025 net sales ($661.3 million)): Consumables and instruments for sample collection, stabilisation, purification and quality control (QIAamp, PAXgene, QIAsymphony, QIAcube Connect), with about 300 kit types. Parse Biosciences (single-cell analysis) joined in December 2025. Q2 2026 sales were $182 million, +9% CER, led by automated consumables.
- **PCR / Nucleic acid amplification** (15% of FY2025 net sales ($309.0 million)): Research and applied PCR kits, enzymes, assays and instruments, including the QIAcuity digital PCR platform, forensics assays and OEM enzymes. QIAcuity consumables grow double digits, but OEM demand and instruments were weaker; Q2 2026 sales were $74 million (-8% CER).
- **Genomics / NGS** (12% of FY2025 net sales ($241.8 million)): Universal NGS panels for any sequencer and the QIAGEN Digital Insights bioinformatics portfolio, strengthened by the Genoox acquisition in May 2025. Q2 2026 sales were $61 million (+2% CER), with universal NGS panels up more than 20% CER.
- **Other** (4% of FY2025 net sales ($74.9 million)): Protein biology products, royalties, intellectual property and freight charges.

## Strategic priorities

- **Grow the five pillars to about $2 billion**: Sample technologies, QuantiFERON, QIAstat-Dx, QIAcuity and QIAGEN Digital Insights made $1.5 billion, about 72% of 2025 sales, and are targeted at about $2 billion by 2028. Management expects them to grow about 7% in 2026.
- **Return to growth in the second half of 2026**: The FY2026 outlook is net sales growth of about 1-2% CER and adjusted diluted EPS of at least $2.43 CER, with H2 growth of about 3-4% from launches and the end of NeuMoDx and Dialunox comparisons.
- **Automation and new instruments**: QIAsymphony Connect and QIAsprint Connect are launched, QIAmini is due in H2 2026, and a fully automated QuantiFERON workflow with Diasorin and Inpeco is targeted for late 2027.
- **AI in bioinformatics and customer service**: QIAGEN launched the QIA Agent AI laboratory assistant in May 2026 and a QDI collaboration with NVIDIA on graph-based AI for target identification and biomarker discovery.
- **Bring bloodstream infection panels to the U.S.**: QIAstat-Dx BCID panels for bloodstream infections are launched in Europe; the first panel was submitted to the FDA in January 2026.
- **New CEO and strategic review**: Jonathan M. Pratt took over as CEO on 1 September 2026 while the Supervisory Board continues a strategic review with independent advisors, with no timetable given.

## Latest results

In Q2 2026 net sales were $535 million, unchanged on a reported and CER basis versus Q2 2025 and ahead of the outlook for an about 2% CER decline. The growth pillars grew about 5% CER while the rest of the portfolio fell 13% CER; instrument sales declined at a low-teens CER rate on cautious U.S. Life Sciences capital spending. Adjusted operating income margin was 29.4% (29.9% a year earlier) and adjusted diluted EPS $0.62. H1 2026 net sales were $1,027 million (+1%, -1% CER). In April 2026 QIAGEN had cut its FY2026 outlook from at least 5% CER sales growth to about 1-2% CER; that outlook was reaffirmed in August.

## Investments and deals

- **Parse Biosciences acquisition**: Acquired 2 December 2025 for $229.1 million: instrument-free single-cell RNA workflows with more than 3,000 customers; expected to exceed a 2026 sales target of about $40 million.
- **Genoox acquisition**: Acquired 23 May 2025: a cloud-based AI platform for clinical genetic testing, integrated into QIAGEN Digital Insights.
- **Capex and IT**: Capex for property, plant and equipment was $201.0 million in 2025 ($167.2 million in 2024), with a multi-year SAP S/4HANA implementation and cyber security investment under way.
- **Shareholder returns**: A $496.7 million synthetic share repurchase completed in January 2026; a dividend of about $72 million paid in July 2026, up 40% per share.
- **Restructuring**: The 2025 Restructuring Program relocates positions and consolidates functions to lower-cost locations, at a total cost of about $60.0 million, of which about $25.0 million expected in 2026.

## Challenges and risks

- **Lower QuantiFERON immigration testing**: Immigration testing is about 10% of QuantiFERON sales (about $50 million); QIAGEN cut about $35 million of it from its 2026 expectations and now sees QuantiFERON steady at around $500 million.
- **Cautious U.S. Life Sciences spending**: About $40 million of 2026 caution from U.S. research customers, OEM ordering volatility and the Middle East conflict; instrument sales fell at a low-teens CER rate in Q2 2026.
- **Tariffs and China**: The 20-F names U.S. tariffs and U.S.-China trade policy as risks; Asia Pacific, Japan and Rest of World sales fell 2% in 2025 on lower demand in China.
- **Research funding**: Sales to universities and government labs depend on grants, particularly from the U.S. NIH; budget cuts could significantly hurt results.
- **Leadership transition**: The CEO change and the open strategic review are flagged as risks to execution and retention.

## What leadership says

> "We achieved solid growth across key pillars, particularly Sample technologies, QIAcuity and QDI, while navigating continued pressure on instrument spending in the U.S." — Thierry Bernard, former Chief Executive Officer, Q2 2026 results release, 5 August 2026

> "My first priority will be to listen to QIAGEN teams and customers, learn more about the business and understand where we can sharpen our choices, strengthen execution and create greater impact." — Jonathan M. Pratt, Chief Executive Officer, CEO appointment press release, 24 August 2026

> "We increased the 2026 dividend by 40% compared with 2025 and continue to evaluate way to deploy capital to the highest-return opportunities." — Roland Sackers, Chief Financial Officer, Q2 2026 results release, 5 August 2026

> "AI is only as valuable as the scientific knowledge behind it." — Thierry Bernard, former Chief Executive Officer, Q2 2026 results call, 6 August 2026


## Where a supplier can help

- **Lower-cost operations under restructuring**: The 2025 Restructuring Program consolidates functions in lower-cost locations; suppliers of shared services, automation or outsourcing can support that move.
- **IT, ERP and cyber security**: The multi-year SAP S/4HANA implementation and cyber security investment create needs for integrators, security tools and data migration help.
- **Launch support for new instruments**: With H2 2026 growth relying on QIAsymphony Connect, QIAsprint Connect, QIAmini and BCID panels, suppliers of components, field service, training and commercial enablement are relevant.
- **AI and knowledge-base tooling**: The QIA Agent assistant and QDI work with NVIDIA point to demand for AI infrastructure, data curation and conversational commerce tooling.
- **A new CEO reviewing choices**: Jonathan M. Pratt's stated aim to sharpen choices and strengthen execution, plus the strategic review, means supplier and portfolio decisions may be revisited.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Annual Report on Form 20-F for the year ended December 31, 2025](https://www.sec.gov/Archives/edgar/data/1015820/000101582026000018/qgen-20251231.htm)

Annual report · 2026-03-20

- QIAGEN N.V. (Venlo, Netherlands; NYSE: QGEN, Frankfurt: QIA) sells "Sample to Insight" solutions: sample preparation, assays, instruments and bioinformatics, to more than 500,000 customers in Life Sciences and molecular diagnostics; about 5,700 employees in over 35 locations at end-2025.
- FY2025 net sales were $2,090.0 million (+6%), with consumables and related revenues at 90% of sales and instruments at 10%; operating income $465.9 million (22.3% margin vs 4.9% in 2024), net income $424.9 million.
- Five growth pillars (Sample technologies, QuantiFERON, QIAstat-Dx, QIAcuity, QIAGEN Digital Insights) made $1.5 billion, about 72% of 2025 sales, and are targeted at about $2 billion by 2028.
- Product groups in 2025: Diagnostic solutions $803.1 million (38%), Sample technologies $661.3 million (32%), PCR/Nucleic acid amplification $309.0 million (15%), Genomics/NGS $241.8 million (12%), Other $74.9 million (4%). QIAstat-Dx sales rose 27% and QuantiFERON-TB 11%.
- By region: Americas $1,086.5 million (+5%, U.S. $998.4 million), EMEA $712.8 million (+10%), Asia Pacific, Japan and Rest of World $290.7 million (-2%, lower demand in China).
- M&A: Genoox (AI clinical genetics software, May 2025) and Parse Biosciences (instrument-free single-cell analysis, December 2025, consideration $229.1 million); $291.2 million net cash paid for both.
- Capital returns and funding: $496.7 million synthetic share repurchase completed January 2026, first annual dividend ($54.2 million) paid July 2025, $750.0 million 2.0% convertible notes due 2032 issued September 2025; capex $201.0 million in 2025.
- Leadership: CEO Thierry Bernard announced in November 2025 he would step down once a successor is appointed; CFO Roland Sackers, Supervisory Board chair Stephen H. Rusckowski.
- Key risks named: U.S. tariffs and U.S.-China trade policy, NIH and other public research funding, competition in QuantiFERON, QIAcuity and QIAstat-Dx, regulatory approvals, cyber security and leadership transition.

### [QIAGEN exceeds Q2 2026 outlook as pillars deliver solid sales growth; reaffirms full-year outlook (Q2 2026 results release)](https://www.sec.gov/Archives/edgar/data/1015820/000101582026000049/exhibit9912026q2pressrelea.htm)

Interim report · 2026-08-05

- Q2 2026 net sales were $535 million, unchanged on a reported and CER basis vs Q2 2025, beating the outlook for an about 2% CER decline; H1 2026 net sales $1,027 million (+1%, -1% CER).
- The growth pillars grew about 5% CER, led by Sample technologies (+9% CER to $182 million, +3% CER excluding Parse), QIAcuity (double-digit CER) and QIAGEN Digital Insights; the rest of the portfolio fell 13% CER (7% excluding NeuMoDx and Dialunox).
- QuantiFERON rose 1% CER to $131 million despite a significant decline in U.S. immigration testing; QIAstat-Dx fell 7% CER against a strong respiratory prior year.
- Adjusted operating income margin 29.4% (29.9% in Q2 2025); adjusted diluted EPS $0.62, above the outlook of at least $0.60 CER; diluted EPS $0.50.
- Instrument sales fell at a low-teens CER rate on cautious U.S. Life Sciences capital spending.
- H1 operating cash flow $301 million; $500 million synthetic share repurchase in January 2026; dividend of about $72 million paid July 2026, up 40% per share; leverage 1.1x.
- FY2026 outlook reaffirmed: net sales growth of about 1-2% CER and adjusted diluted EPS of at least $2.43 CER; Q3 2026 sales growth about 1-2% CER.
- Launches: QIA Agent AI lab assistant (May 2026), QDI collaboration with NVIDIA, QIAsymphony Connect and QIAsprint Connect, QIAmini due H2 2026, automated QuantiFERON workflow with Diasorin and Inpeco targeted for late 2027.

### [QIAGEN Q2 2026 results call transcript (prepared remarks)](https://s28.q4cdn.com/125951340/files/doc_financials/2026/q2/20260806_QIAGEN-Q2-2026-RESULTS-TRANSCRIPT.pdf)

Executive talk · Thierry Bernard, Chief Executive Officer (with Roland Sackers, Chief Financial Officer) · 2026-08-06

- Prepared remarks of CEO Thierry Bernard and CFO Roland Sackers on the Q2 2026 results call (6 August 2026); the published transcript stops before Q&A.
- Q2 net sales $535 million, unchanged at CER and ahead of the outlook for an approximately 2% decline; adjusted diluted EPS 62 cents.
- Growth pillars +5% CER; QuantiFERON back to growth (+1% CER) despite lower immigration testing in the U.S. and Middle East; QIAstat-Dx -7% CER on a tough respiratory comparison.
- Regions: Americas +1% CER, EMEA -2% CER (Germany, France, Italy down), Asia-Pacific -2% CER with China down low-teens and Japan up high-teens.
- Adjusted operating margin 29.4%, up 200 basis points from 27.4% in Q1 2026; dividend raised 40% to 35 cents per share.
- H2 bridge: CER growth from -1% in H1 to about 3-4% in H2: about 2 points from the end of NeuMoDx/Dialunox headwinds, about 2 points from launches, about half a point from Parse and U.S. Life Sciences.
- Launch pipeline: QIAsymphony Connect, QIAsprint Connect, QIAmini (this fall), BCID bloodstream panels (33 pathogens, 28 resistance markers), QIAcuity gene expression, automated QuantiFERON workflow in late 2027, QDI and NVIDIA AI collaboration.
- Tariff refunds net of customer refunds could add about 2 cents EPS; about 47% of annual sales come in H1 and 53% in H2.

### [QIAGEN preliminary Q1 2026 results call transcript (prepared remarks)](https://s28.q4cdn.com/125951340/files/doc_downloads/2026/04/20260428_QIAGEN-Q1-2026-RESULTS-TRANSCRIPT.pdf)

Executive talk · Thierry Bernard, Chief Executive Officer (with Roland Sackers, Chief Financial Officer) · 2026-04-28

- Prepared remarks of CEO Thierry Bernard and CFO Roland Sackers on the preliminary Q1 2026 results call (28 April 2026), held after a guidance cut.
- Q1 net sales $492 million, +2% reported but -1% CER, below the outlook for at least 1% CER growth; adjusted EPS 54 cents in line.
- Cause: QuantiFERON -5% CER on sharply lower immigration testing in the U.S. and Middle East, plus caution among U.S. Life Sciences customers; "4 of the 5 pillars achieved or exceeded our expectations".
- FY2026 outlook cut from at least 5% CER sales growth to about 1-2% CER, and adjusted EPS from at least 2 dollars and 50 cents to at least 2 dollars and 43 cents at CER.
- QuantiFERON 2026 now expected steady at around $500 million vs about $535 million before; immigration testing is about 10% of QuantiFERON sales (about $50 million), cut by about $35 million.
- About $40 million of U.S. Life Sciences caution: $15-20 million research customers, $20 million OEM ordering volatility (including U.S. government agencies), a few million from the Middle East conflict.
- Pillars expected to grow about 7% in 2026 and are about 75% of sales; H2 growth seen at about 4% CER on launches, end of NeuMoDx/Dialunox headwinds, QuantiFERON and Parse.
- Product news: QIAsprint Connect launched in February, QIAsymphony Connect full IVD rollout mid-year, QIAmini later in 2026, first BCID panel submitted to the FDA in January.

### [QIAGEN appoints Jonathan M. Pratt as Chief Executive Officer (press release, Form 6-K Exhibit 99.1)](https://www.sec.gov/Archives/edgar/data/1015820/000101582026000056/exhibit991ceoappointment08.htm)

Report · 2026-08-24

- QIAGEN appointed Jonathan M. (Jon) Pratt as Chief Executive Officer effective 1 September 2026, succeeding Thierry Bernard, who left the Managing Board that day and supports the transition through year-end.
- Pratt brings more than 25 years in life sciences, laboratory technologies and healthcare: most recently President and CEO of Filtration Group (sold to Parker-Hannifin in August 2026), previously SVP of the Waters Division at Waters, President of Beckman Coulter Life Sciences (Danaher) and senior roles at Pall.
- He will be proposed as Managing Director at an Extraordinary General Meeting planned for Q4 2026.
- Pratt's stated first priority: to listen to teams and customers and understand "where we can sharpen our choices, strengthen execution and create greater impact".
- Supervisory Board chair Stephen H. Rusckowski cited his record of "strengthening commercial execution and operational performance".
- The Supervisory Board's strategic review, with independent financial and legal advisors, continues, evaluating options against QIAGEN's standalone plan.
- QIAGEN reaffirmed its Q3 and full-year 2026 outlook; about 5,500 employees as of 30 June 2026.

## Questions about QIAGEN

### What does QIAGEN do?

QIAGEN sells Sample to Insight solutions: sample preparation kits, assays, instruments and bioinformatics software for Life Sciences research and molecular diagnostics, to more than 500,000 customers.

### What is QIAGEN's revenue?

FY2025 net sales were $2,090.0 million, up 6%, with operating income of $465.9 million. H1 2026 net sales were $1,027 million.

### How many employees does QIAGEN have?

About 5,500 employees as of 30 June 2026, across more than 35 locations.

### Who leads QIAGEN?

Jonathan M. Pratt has been CEO since 1 September 2026, succeeding Thierry Bernard. Roland Sackers is CFO and Stephen H. Rusckowski chairs the Supervisory Board.

### What is QIAGEN's strategy?

QIAGEN focuses on five growth pillars, targeted at about $2 billion of sales by 2028, and on solid profitable growth, while its Supervisory Board runs a strategic review.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
